176:
183:
CER-001 is designed to mimic the natural structure and function of nascent HDL, also known as pre-beta HDL. This mimicry stimulates cholesterol efflux from macrophages, captures cholesterol and eliminates it via reverse lipid transport (RLT) pathway, also known as
394:
365:
682:
278:
402:
132:
249:
309:"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial"
476:"CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice"
425:"Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project"
373:
517:"The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency"
690:
135:. CER-001 is also under investigation as possible agent for treating hyperinflammatory states based on lipid profile alterations due to
200:
in mice investigated whether LCAT deficiency affects the catabolic behavior of CER-001 and evaluated the effects of the substance on
286:
656:
185:
257:
116:
104:
197:
120:
42:
859:
423:
Stasi A, Fiorentino M, Franzin R, Staffieri F, Carparelli S, Losapio R, et al. (November 2023).
164:
515:
Pavanello C, Turri M, Strazzella A, Tulissi P, Pizzolitto S, De Maglio G, et al. (March 2022).
250:"EU/3/21/2490 - orphan designation for treatment of lecithin-cholesterol acyltransferase deficiency"
764:"CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency"
607:"Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study"
307:
Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, et al. (December 2014).
124:
59:
328:
221:
220:
CER-001 was given in clinical human studies by intravenous infusion. It did not appear to affect
835:
783:
744:
638:
546:
497:
456:
346:
175:
148:
68:
825:
817:
775:
762:
Ossoli A, Strazzella A, Rottoli D, Zanchi C, Locatelli M, Zoja C, et al. (2020-12-09).
734:
724:
628:
618:
585:
577:
536:
528:
487:
474:
Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, et al. (January 2014).
446:
436:
336:
320:
492:
475:
128:
806:"Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings"
212:
typically associated with LCAT deficiency and mitigate renal damages in LCAT deficiency.
564:
Stasi A, Franzin R, Fiorentino M, Squiccimarro E, Castellano G, Gesualdo L (June 2021).
451:
424:
830:
805:
739:
712:
633:
606:
590:
565:
541:
516:
341:
308:
205:
201:
112:
853:
160:
156:
209:
152:
779:
660:
566:"Multifaced Roles of HDL in Sepsis and SARS-CoV-2 Infection: Renal Implications"
229:
108:
605:
Faguer S, Del Bello A, Danet C, Renaudineau Y, Izopet J, Kamar N (2022-09-26).
441:
324:
821:
623:
581:
225:
729:
332:
839:
787:
763:
748:
642:
550:
501:
460:
350:
136:
79:
88:
22:
683:"Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001"
532:
151:(ApoA1), the main structural protein of natural HDL, together with two
147:
CER-001 is an artificially synthesized mimetic of recombinant human
395:"Abionyx Pharma announces success in fighting sepsis-triggered AKI"
174:
366:"CER-001 identified as potential treatment for septic patients"
804:
Keyserling CH, Barbaras R, Benghozi R, Dasseux JL (May 2017).
279:"CER-001 for Familial Primary Hypoalphalipoproteinemia"
133:
lecithin cholesterol acyltransferase (LCAT) deficiency
78:
58:
53:
41:
33:
28:
799:
797:
659:. Abionyx Pharma SA, Balma, France. Archived from
67:
283:NIHR Innovation Observatory Evidence Briefing
8:
21:
570:International Journal of Molecular Sciences
829:
738:
728:
632:
622:
589:
540:
491:
450:
440:
340:
319:(46) (published 2024-04-29): 3277–3286.
204:associated with LCAT deficiency. In the
241:
87:
20:
816:(5) (published 2017-02-17): 483–491.
768:Metabolism: clinical and experimental
713:"Non-clinical development of CER-001"
527:(3) (published 2021-11-11): 364–370.
493:10.1016/j.atherosclerosis.2013.10.018
486:(1) (published 2013-11-08): 110–118.
7:
232:parameters and is considered safe.
14:
435:(1) (published 2023-11-02): 392.
16:High-density lipoprotein mimetic
115:for the potential treatment of
370:European Pharmaceutical Review
179:Mechanism of action of CER-001
1:
780:10.1016/j.metabol.2020.154464
208:, it appeared to improve the
186:reverse cholesterol transport
111:status. It is in early-stage
521:Journal of Internal Medicine
401:. 2023-01-16. Archived from
810:Clinical Drug Investigation
876:
442:10.1186/s12916-023-03057-5
399:european-biotechnology.com
285:. May 2018. Archived from
822:10.1007/s40261-017-0506-3
717:Frontiers in Pharmacology
711:Barbaras R (2015-10-06).
624:10.3389/fphar.2022.936659
611:Frontiers in Pharmacology
254:European Medicines Agency
117:hypoalphalipoproteinaemia
730:10.3389/fphar.2015.00220
681:Helfand C (2014-01-03).
364:Eckford C (2023-01-17).
325:10.1093/eurheartj/ehu171
105:high-density lipoprotein
582:10.1093/ndt/gfac067.086
121:acute coronary syndrome
107:(HDL) mimetic that has
313:European Heart Journal
180:
178:
192:Pre-clinical studies
165:phosphatidylglycerol
576:(11): gfac067.086.
171:Mechanism of action
125:acute kidney injury
25:
533:10.1111/joim.13404
222:clinical chemistry
198:pre-clinical study
181:
149:apolipoprotein AI
103:is a recombinant
98:
97:
867:
844:
843:
833:
801:
792:
791:
759:
753:
752:
742:
732:
708:
702:
701:
699:
698:
689:. Archived from
678:
672:
671:
669:
668:
653:
647:
646:
636:
626:
602:
596:
595:
593:
561:
555:
554:
544:
512:
506:
505:
495:
471:
465:
464:
454:
444:
420:
414:
413:
411:
410:
391:
385:
384:
382:
381:
372:. Archived from
361:
355:
354:
344:
304:
298:
297:
295:
294:
275:
269:
268:
266:
265:
256:. Archived from
246:
91:
71:
37:CER-001, CER 001
26:
24:
875:
874:
870:
869:
868:
866:
865:
864:
850:
849:
848:
847:
803:
802:
795:
761:
760:
756:
710:
709:
705:
696:
694:
680:
679:
675:
666:
664:
655:
654:
650:
604:
603:
599:
563:
562:
558:
514:
513:
509:
480:Atherosclerosis
473:
472:
468:
422:
421:
417:
408:
406:
393:
392:
388:
379:
377:
363:
362:
358:
306:
305:
301:
292:
290:
277:
276:
272:
263:
261:
248:
247:
243:
238:
218:
216:Clinical trials
202:kidney diseases
194:
188:(RCT) pathway.
173:
145:
129:atherosclerosis
113:clinical trials
94:
74:
44:
17:
12:
11:
5:
873:
871:
863:
862:
852:
851:
846:
845:
793:
754:
703:
687:Fierce Biotech
673:
648:
597:
556:
507:
466:
415:
386:
356:
299:
270:
240:
239:
237:
234:
217:
214:
193:
190:
172:
169:
144:
141:
96:
95:
93:
92:
84:
82:
76:
75:
73:
72:
64:
62:
56:
55:
51:
50:
47:
45:administration
39:
38:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
872:
861:
858:
857:
855:
841:
837:
832:
827:
823:
819:
815:
811:
807:
800:
798:
794:
789:
785:
781:
777:
773:
769:
765:
758:
755:
750:
746:
741:
736:
731:
726:
722:
718:
714:
707:
704:
693:on 2020-10-22
692:
688:
684:
677:
674:
663:on 2020-08-11
662:
658:
652:
649:
644:
640:
635:
630:
625:
620:
616:
612:
608:
601:
598:
592:
587:
583:
579:
575:
571:
567:
560:
557:
552:
548:
543:
538:
534:
530:
526:
522:
518:
511:
508:
503:
499:
494:
489:
485:
481:
477:
470:
467:
462:
458:
453:
448:
443:
438:
434:
430:
426:
419:
416:
405:on 2023-01-24
404:
400:
396:
390:
387:
376:on 2023-01-17
375:
371:
367:
360:
357:
352:
348:
343:
338:
334:
330:
326:
322:
318:
314:
310:
303:
300:
289:on 2024-03-20
288:
284:
280:
274:
271:
260:on 2022-03-16
259:
255:
251:
245:
242:
235:
233:
231:
227:
223:
215:
213:
211:
207:
203:
199:
191:
189:
187:
177:
170:
168:
166:
162:
158:
157:sphingomyelin
155:, which are:
154:
153:phospholipids
150:
142:
140:
138:
134:
130:
126:
122:
118:
114:
110:
106:
102:
90:
86:
85:
83:
81:
77:
70:
66:
65:
63:
61:
57:
52:
48:
46:
40:
36:
32:
29:Clinical data
27:
19:
860:Orphan drugs
813:
809:
771:
767:
757:
720:
716:
706:
695:. Retrieved
691:the original
686:
676:
665:. Retrieved
661:the original
651:
614:
610:
600:
573:
569:
559:
524:
520:
510:
483:
479:
469:
432:
429:BMC Medicine
428:
418:
407:. Retrieved
403:the original
398:
389:
378:. Retrieved
374:the original
369:
359:
316:
312:
302:
291:. Retrieved
287:the original
282:
273:
262:. Retrieved
258:the original
253:
244:
219:
210:dyslipidemia
195:
182:
146:
100:
99:
69:1383435-67-3
18:
230:coagulation
206:mouse model
109:orphan drug
54:Identifiers
34:Other names
774:: 154464.
697:2024-03-12
667:2024-04-10
617:: 936659.
409:2024-03-20
380:2024-03-09
293:2024-03-20
264:2024-03-11
236:References
226:hematology
60:CAS Number
657:"CER-001"
333:1522-9645
161:palmitoyl
143:Chemistry
43:Routes of
854:Category
840:28213743
788:33309714
749:26500552
643:36225555
551:34761839
502:24401224
461:37915050
452:10621167
351:24780501
137:COVID-19
80:DrugBank
49:Infusion
831:5394142
740:4594020
723:: 220.
634:9550000
591:9383927
542:9299003
342:4258222
127:(AKI),
123:(ACS),
101:CER-001
89:DB18538
23:CER-001
838:
828:
786:
747:
737:
641:
631:
588:
549:
539:
500:
459:
449:
349:
339:
331:
159:and di
329:eISSN
836:PMID
784:PMID
745:PMID
639:PMID
547:PMID
498:PMID
457:PMID
347:PMID
131:and
826:PMC
818:doi
776:doi
772:116
735:PMC
725:doi
629:PMC
619:doi
586:PMC
578:doi
537:PMC
529:doi
525:291
488:doi
484:232
447:PMC
437:doi
337:PMC
321:doi
228:or
856::
834:.
824:.
814:37
812:.
808:.
796:^
782:.
770:.
766:.
743:.
733:.
719:.
715:.
685:.
637:.
627:.
615:13
613:.
609:.
584:.
574:22
572:.
568:.
545:.
535:.
523:.
519:.
496:.
482:.
478:.
455:.
445:.
433:21
431:.
427:.
397:.
368:.
345:.
335:.
327:.
317:35
315:.
311:.
281:.
252:.
224:,
196:A
167:.
139:.
119:,
842:.
820::
790:.
778::
751:.
727::
721:6
700:.
670:.
645:.
621::
594:.
580::
553:.
531::
504:.
490::
463:.
439::
412:.
383:.
353:.
323::
296:.
267:.
163:-
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
